Alvotech Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.01.24	Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 (GlobeNewswire)
10.01.24	STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara (GlobeNewswire)
03.01.24	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) (GlobeNewswire)
29.11.23	Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
28.11.23	Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update (GlobeNewswire)
21.11.23	Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET (GlobeNewswire)
14.11.23	Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab) (GlobeNewswire)
10.11.23	STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara (GlobeNewswire)
07.11.23	Alvotech to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
12.10.23	Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 (GlobeNewswire)
05.10.23	Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland (GlobeNewswire)
03.10.23	Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) (GlobeNewswire)
25.09.23	Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® (GlobeNewswire)
20.09.23	Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) (GlobeNewswire)
11.09.23	Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
05.09.23	Alvotech Announces Changes to the Leadership Team (GlobeNewswire)
30.08.23	Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update (GlobeNewswire)
29.08.23	Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt (GlobeNewswire)
22.08.23	Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET (GlobeNewswire)
31.07.23	Alvotech Completes $100 Million Convertible Bond Private Placement (GlobeNewswire)
24.07.23	Teva, Alvotech Announce Expanded Strategic Partnership For Biosimilars (RTTNews)
24.07.23	Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership (GlobeNewswire)
29.06.23	Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 (GlobeNewswire)
14.06.23	ALVO, ALVOW INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO, ALVOW (PR Newswire)
12.06.23	Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® (GlobeNewswire)
31.05.23	Alvotech to Participate in Jefferies Healthcare Conference (GlobeNewswire)
27.05.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVOW (PR Newswire)
24.05.23	Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe (GlobeNewswire)
19.05.23	Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update (GlobeNewswire)
17.05.23	Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit (GlobeNewswire)
15.05.23	Alvotech Issues Annual Equality Report Covering 2022 (GlobeNewswire)
10.05.23	Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept) (GlobeNewswire)
05.05.23	Alvotech S.A. Annual General Meeting to be held June 6, 2023 (GlobeNewswire)
04.05.23	Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® (GlobeNewswire)
03.05.23	Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET (GlobeNewswire)
19.04.23	Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer (GlobeNewswire)
14.04.23	Teva's Partner Alvotech Receives Complete Response Letter For AVT02 BLA (RTTNews)
14.04.23	Alvotech Provides Regulatory Update on AVT02 Biologics License Application (GlobeNewswire)
31.03.23	Biotech Stocks Facing FDA Decision In April 2023 (RTTNews)
28.03.23	Alvotech Provides Update on Corporate Sustainability Framework (GlobeNewswire)
17.03.23	Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
01.03.23	Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update (GlobeNewswire)
28.02.23	Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 (GlobeNewswire)
14.02.23	Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market (GlobeNewswire)
10.02.23	Settlement of Alvotech Private Share Placement Completed (GlobeNewswire)
09.02.23	EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
24.01.23	Alvotech, Bioventure Announce Approval For Humira Biosimilar Simlandi In Saudi (RTTNews)
06.01.23	Alvotech : FDA Accepts BLA For AVT04, Proposed Biosimilar To Stelara (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alvotech Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten